Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials - PubMed https://pubmed.ncbi.nlm.nih.gov/37024129/?dopt=Abstract https://pubmed.ncbi.nlm.nih.gov/37024129/#msdynttrid=GKdH2JNMPLeiwqSZXvZ0yQiGE4saa-kLWNPxIkBVzZ8 “This study further separates the effect of #diabetes treatments on blood #glucose levels and important outcomes. #SGLT2 inhibitors and #GLP1 receptor agonists reduce all-cause and #cardiovascular mortality, as well as other cardiac-related problems.”

#SGLT2 inhibitors mitigate #kidney tubular #metabolism and mTORC1 perturbations in type 2 #diabetes. #t2d #glucose #nephropathy https://www.jci.org/articles/view/164486 and commentary https://www.jci.org/articles/view/167700

RT @CMEInstitute
🩺 @Kidney_boy and @ErinMichos discuss 3 patient cases and how regular screening of UACR and adding finerenone to #SGLT2 inhibitors can greatly impact #T2D at risk for #CKD.

🎥 Click to Watch: https://bit.ly/3XUvDwI

RT @Medicijngebruik@twitter.com

Op de valreep het #Medicijnjournaal december met o.a. bijwerkingen geneesmiddelen op het gebit, gevaren en herkennen van excessief gebruik #lachgas en #werkingsmechanisme en #effectiviteit van #SGLT2-remmers bij #hartfalen.
#pictogrammengeneesmiddelen
https://youtu.be/SgpcalDGjcQ

🐦🔗: https://twitter.com/Medicijngebruik/status/1608021600322072576

ADA Standards of Care in #Diabetes 2023 just released. Updates include:
Emphasis on supporting up to 15% #weight loss
New #hypertension diagnosis cut-offs
Role of #SGLT2 inhibitor use in HFpEF and HFrEF
Lower #LDL goals for high-risk individuals

https://diabetesjournals.org/care/issue/46/Supplement_1

Looking forward to speaking for this free #CME session w/ @PlatformQHealth & @goKDIGO on the impact that #SGLT2 inhibitors can have on the progression of #ChronicKidneyDisease! Register now: https://www.cardiocarelive.com/app/signup/120522_CSLCCL_CME_SGLT2_Reg/formPage/0?refCode=soc_CCL_all_120522_BeyondACEisandARBsFACULTYCOPY

#SGLT2-Inhibitoren können ein Fortschreiten von Nierenerkrankungen und akuten Nierenschäden verringern – und das unabhängig vom #Diabetes-Risiko. Das bestätigt eine aktuelle Studie.
http://docc.hk/xk9una

New meta-analysis finds #SGLT2 inhibitors are beneficial in patients with #CKD or #HF irrespective of diabetes status.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02074-8/fulltext